S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
Log in
NASDAQ:VRTX

Vertex Pharmaceuticals Stock Forecast, Price & News

$225.55
-0.57 (-0.25 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$224.44
Now: $225.55
$227.42
50-Day Range
$224.04
MA: $231.16
$237.00
52-Week Range
$197.47
Now: $225.55
$306.08
Volume70,575 shs
Average Volume1.87 million shs
Market Capitalization$58.65 billion
P/E Ratio28.48
Dividend YieldN/A
Beta0.79
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals logo

MarketRank

Overall MarketRank

2.57 out of 5 stars

Medical Sector

7th out of 67 stocks

Pharmaceutical Preparations Industry

3rd out of 31 stocks

Analyst Opinion: 4.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VRTX
CUSIP92532F10
Phone617-341-6100
Employees3,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.16 billion
Cash Flow$4.87 per share
Book Value$23.66 per share

Profitability

Net Income$1.18 billion

Miscellaneous

Market Cap$58.65 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$225.55
-0.57 (-0.25 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

How has Vertex Pharmaceuticals' stock price been impacted by COVID-19?

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VRTX stock has increased by 2.4% and is now trading at $225.55.
View which stocks have been most impacted by COVID-19
.

Is Vertex Pharmaceuticals a buy right now?

30 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 6 hold ratings, 23 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vertex Pharmaceuticals stock.
View analyst ratings for Vertex Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Vertex Pharmaceuticals?

Wall Street analysts have given Vertex Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vertex Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Vertex Pharmaceuticals
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings data on Thursday, October, 29th. The pharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.96 by $0.68. The pharmaceutical company earned $1.54 billion during the quarter, compared to analysts' expectations of $1.48 billion. Vertex Pharmaceuticals had a return on equity of 28.55% and a net margin of 38.51%. The company's revenue for the quarter was up 61.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.23 earnings per share.
View Vertex Pharmaceuticals' earnings history
.

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals announced that its Board of Directors has initiated a stock buyback program on Wednesday, July 31st 2019, which authorizes the company to repurchase $500,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 1.2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's leadership believes its shares are undervalued.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Thursday, October, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $6-6.2 billion, compared to the consensus revenue estimate of $6.02 billion.

What price target have analysts set for VRTX?

30 equities research analysts have issued 12 month price targets for Vertex Pharmaceuticals' stock. Their forecasts range from $230.00 to $340.00. On average, they expect Vertex Pharmaceuticals' share price to reach $289.66 in the next year. This suggests a possible upside of 28.4% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Are investors shorting Vertex Pharmaceuticals?

Vertex Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 3,250,000 shares, an increase of 21.3% from the December 15th total of 2,680,000 shares. Based on an average trading volume of 2,110,000 shares, the days-to-cover ratio is presently 1.5 days.
View Vertex Pharmaceuticals' Short Interest
.

Who are some of Vertex Pharmaceuticals' key competitors?

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the following people:
  • Dr. Jeffrey Marc Leiden, Exec. Chairman (Age 65, Pay $4.88M)
  • Dr. Reshma Kewalramani, CEO, Pres & Director (Age 48, Pay $2.03M)
  • Mr. Charles F. Wagner Jr., Exec. VP & CFO (Age 53, Pay $1.66M)
  • Mr. Amit K. Sachdev, Exec. VP & Chief Patient Officer (Age 53, Pay $1.41M)
  • Mr. Stuart A. Arbuckle, Exec. VP & Chief Commercial Officer (Age 55, Pay $2.07M)
  • Mr. Paul M. Silva, Sr. VP & Corp. Controller (Age 55, Pay $833.97k)
  • Dr. David M. Altshuler, Exec. VP of Global Research & Chief Scientific Officer (Age 56)
  • Mr. Mike Tirozzi, SVP and Chief Information & Data Officer
  • Mr. Michael J. Parini, Exec. VP & Chief Admin., Legal and Bus. Devel. Officer (Age 46)
  • Mr. Michael Partridge, Sr. VP of Investor Relations

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Gateway Investment Advisers LLC (0.05%), Cullinan Associates Inc. (0.04%), State of Alaska Department of Revenue (0.02%), LVM Capital Management Ltd. MI (0.01%), Louisiana State Employees Retirement System (0.01%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals
.

Which major investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including Chesley Taft & Associates LLC, State of Alaska Department of Revenue, Cypress Capital Group, Gateway Investment Advisers LLC, Vigilant Capital Management LLC, Huntington National Bank, Kovack Advisors Inc., and First Citizens Bank & Trust Co.. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, and Yuchun Lee.
View insider buying and selling activity for Vertex Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Vertex Pharmaceuticals stock?

VRTX stock was acquired by a variety of institutional investors in the last quarter, including LVM Capital Management Ltd. MI, Louisiana State Employees Retirement System, Enterprise Trust & Investment Co, Polianta Ltd, Cullinan Associates Inc., Strategic Wealth Designers, IFM Investors Pty Ltd, and Investment House LLC.
View insider buying and selling activity for Vertex Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $225.55.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $58.65 billion and generates $4.16 billion in revenue each year. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Vertex Pharmaceuticals employs 3,000 workers across the globe.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is www.vrtx.com.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.